National Institute Of Pharmaceutical Education And Research, Raebareli

Fifty of the 150 masters seats NIPER Raebareli put into the 2026-27 counselling carried no fellowship, and the fee is identical whichever column your allotment lands in. One whole programme, M.Tech. Medical Devices, was offered with no funded seat at all, and it still had 11 places open after four phases of national counselling had run.

The address is the second thing to settle. Teaching happens at a transit campus in Sarojini Nagar, Lucknow, which is why the ranking framework files the institute under Lucknow while the permanent campus at Vinayak Pur in Raebareli is still being finished. Every hostel, fee and commute decision below is a Lucknow decision until the institute says otherwise.

The institute is an autonomous Institute of National Importance established in 2008 under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilisers, and it has been functioning from its transit campus at Sarojini Nagar, Lucknow since July 2018, per the NIPER JEE 2026 Masters information brochure. The same section of that brochure measures the transit site at 5 acres, holding academic and administrative blocks, separate hostel blocks for boys and girls and a cafeteria, and describes the permanent campus as nearing completion at 48.5 acres with a further 52 acres proposed for a second phase. The foundation stone for that campus was laid on 12 January 2024, announced on the institute's home page, and its director Prof. Shubhini A. Saraf places it at Vinayak Pur, Raebareli in her message.

Statutory standing is the other half of the picture, and it predates the campus by a decade. Parliament passed the founding law ten years before this campus opened, as Act No. 13 of 1998, gazetted under registration No. DL-33004/98 on 26 June 1998 and amended twice since, in 2007 and in 2021. The institute republishes that law with its statutes, ordinance and Council rules on a single NIPER Act page. Day to day, this campus was not left to find its own feet: the Central Drug Research Institute at Lucknow was named its mentor institute for management support and as the nodal point for the Ministry, on the Government of India's science and technology portal entry for the institute. That relationship is with a Lucknow laboratory, not a Raebareli one, and it explains a good deal about where this campus ended up.

The research brief is narrower than the institute's name suggests, and it is worth reading before you set a preference. Work here is pointed at neglected diseases including tuberculosis, at neurodegenerative disorders such as Alzheimer's and Parkinson's, at nanoformulations built to carry drugs across to the brain, and at the neurological damage done by arsenic, copper and pesticide exposure, set out department by department in the Masters information brochure. The same section counts nearly 700 research and review papers published in the last five years and 43 patents filed since the institute opened, of which 14 have been granted.

Nine masters programmes shared the 150 seats the last counselling offered here, and two of them exist in a shape you will not find at any sibling campus. Six run as M.S. (Pharm.) and three as M.Tech., with no M.Pharm. and no management degree anywhere on the grid, in the NIPER JEE 2026 seat matrix for masters programmes. Read the two right-hand columns of the table below as the real course list, because they decide what the degree costs you.

Two rows in that grid are unique in the system. Regulatory Affairs is ticked for no institute except this one in either the funded or the unfunded seat availability table of the Masters information brochure, so a candidate who wants that degree from a NIPER has exactly one address. Medical Devices runs the other way: five of the seven institutes offered it with a fellowship attached and Raebareli offered none, which is why its whole intake of 20 sits in the unfunded column.

The bill itself is a system-wide document rather than an institute one, printed head by head in the same brochure. What changes at Raebareli is not the number but whether anything comes back against it every month.

Three of those heads are optional, and the brochure marks them with an asterisk rather than saying so plainly: hostel admission at ₹3,496, hostel rent at ₹4,593 and electricity at ₹5,500, all waived for a student who does not opt for hostel accommodation, in the same brochure. A candidate with family in Lucknow can therefore cut the two-year bill without asking anyone's permission. Foreign nationals sit outside the rupee schedule altogether at 2500 US dollars on admission and 1300 US dollars each later semester, in section 4.1.3 of the same document, and that footnote is closed to them: a foreign candidate is counted as a hosteller even if no room is taken.

A doctorate here costs ₹1,22,367 before admission and ₹71,705 a semester after that, or ₹96,345 and ₹45,683 where tuition is waived, in the NIPER JEE 2026 Ph.D. information brochure. Tuition is unchanged from the masters at ₹26,022; what widens the gap is bench time and a room, since the doctoral schedule in that same brochure prices the laboratory head at ₹22,960 and hostel rent at ₹7,654 a semester against the masters figures in the Masters information brochure. One figure the system brochure leaves open, this institute states: thesis evaluation costs ₹11,500 at submission, in its own direct Ph.D. advertisement.

No part of the masters admission is decided on this campus. The paper, the merit list and the counselling all belong to the NIPER JEE office at Mohali, and Raebareli enters the process only as one of seven names a candidate ranks in the common online counselling, per the NIPER JEE 2026 Masters information brochure. Its own admission page makes no attempt to add to that, beyond a helpline on +91-8810795920.

Two gates stand in front of the entrance score, and a good mark on the paper repairs a shortfall in neither. One is the marksheet; the other is a national fellowship scorecard.

That waiver matters more at this campus than at most, because three of its disciplines are written to take medical and veterinary graduates in the first place. Which bachelor's degree you hold decides which of the nine doors is even open, and the range is wider here than at a pharmacy department: Medicinal Chemistry takes a B.Pharm. or an M.Sc. in organic chemistry, Pharmacology & Toxicology adds B.V.Sc. and M.B.B.S., Regulatory Toxicology adds B.V.Sc. and M.B.B.S. to a list of life-science masters, and Regulatory Affairs is the most open of the lot, admitting B.E. and B.Tech. graduates in biotechnology, biomedical or chemical engineering alongside M.B.B.S., B.D.S., B.V.Sc. and a long list of M.Sc. subjects, all set out discipline by discipline on the institute's courses page. An engineering graduate with a GATE score has a route into Regulatory Affairs that exists nowhere else in the system.

The doctoral side has two entrances and only one of them goes through NIPER JEE. The institute runs its own direct admission under Advertisement No. 01/2026, and the condition there is that you arrive with your own money: a CSIR-UGC NET award with lectureship-only results excluded, a DBT-JRF in the A category, a DST-INSPIRE fellowship or an ICMR-JRF that is not tied to working in ICMR projects. Applications cost ₹500 and go by email to the academics office rather than through any portal. The most recent round took applications until 21 August 2026, interviewed shortlisted candidates on 25 August 2026 and admitted them on 28 August 2026, so the whole thing runs inside a week.

A closing rank for this institute does not exist to be quoted. NIPER JEE produces one national merit list, counselling allots against it phase by phase, and neither the office at Mohali nor this campus reports where any of its queues stopped, so a category-wise cutoff table for Raebareli has been reconstructed by whoever is showing it to you.

There is harder evidence than an estimate, and it is sitting in plain sight on the counselling portal. Ahead of each round the office publishes what is still unfilled, institute by institute, and Raebareli's page in those three sheets shows exactly which of its queues emptied and in what order.

Read the last row against the first and the order is unmistakable. The funded Pharmaceutics, Pharmaceutical Analysis, Pharmacology & Toxicology and Regulatory Affairs queues had all closed by the fourth round. What empties last on this campus is the column with no money attached to it.

Then the counselling ended and the seats had not. The institute ran an online spot round of its own on 18 August 2026 for 11 remaining M.Tech. Medical Devices places, split as 5 unreserved, 4 OBC and 2 SC, and it narrowed the field twice over: a candidate had to be on the waiting list with a valid NIPER JEE 2026 rank, must not have accepted a seat anywhere in the system, and had to be GPAT-qualified in the relevant category, in its on-spot counselling notice. A GATE or NET scorecard that would have carried you through the main counselling did not qualify you for this round.

That round left behind the closest thing to a real cutoff this institute has ever published. The shortlists it released carry each applicant's NIPER JEE 2026 rank, and they reach a long way down: the unreserved list runs from 1359 to 3281, the OBC list from 1359 to 3459 and the SC list from 1873 to 3287. Those were the ranks still in contention for a place on this campus in the third week of August. Read them for what they are, though. They describe an unfunded programme that four phases of counselling could not fill, not the funded Pharmaceutics or Medicinal Chemistry seats, which closed earlier and much higher up the list.

The institute's own placement cell page carries a four-year table, and the line that matters most in it has stopped moving. Median salary reads ₹4,50,000 for the 2022-24 batch and ₹4,50,000 again for 2023-25, the latter against 64 placements among the 109 students who graduated. That is a median for the placed group; no average and no highest offer appears anywhere in the institute's own documents.

Read the placed column and the median column together and neither is trending. The count went 54, then 53, then 69, then back down to 64, while the median climbed once from ₹4,00,000 and then held at ₹4,50,000 for two consecutive batches, on the same placement page. Cohorts this size are small enough that a handful of offers moves the whole line, which is the argument for treating this as a flat market rather than a direction.

One row of that table disagrees with the institute's own filing to the government, and it is worth knowing which to trust. The placement page puts the 2020-22 batch at 54 placed on a median of ₹4,00,000, while the NIRF 2025 data submission records 55 placed on a median of ₹4,12,500 for the same cohort. The three later batches match to the rupee across both documents, in that filing and in the NIRF 2026 data submission, so the disagreement is confined to the oldest line.

Recruiters are named, which is more than several NIPERs manage. Students of the 2024-25 year were taken by AstraZeneca, Sun Pharma, Dr Reddy's, Jodas Expoim, Glenmark, Aragen, Sai Life Sciences, CI Scientist, Cadila and Heterolabs, and the institute lists Macleods, Aragen, INTAS and Sun Pharma as its prime campus recruiters, in the Masters information brochure. Formulation and analytical roles dominate that list; there is no consulting or finance recruiter on it, and nothing about it suggests an exit from the bench.

One sentence in that same brochure should be checked against the filings rather than taken on trust: it says more than 30% of students go on to a doctoral programme. The ranking submission puts 25 of the 109 who graduated in 2024-25 into higher study and 34 of the 108 in the year before, in the NIRF 2026 data submission, so the brochure is describing the earlier batch rather than the current one.

The grid that governed allotment is public, and it cuts every discipline twice, first by fellowship and then by category. That double split is the thing to hold on to: a funded Pharmaceutics seat and an unfunded one are separate blocks with separate queues, even though the degree and the bill are identical.

The disability block carries the same split as everything else here. Seven supernumerary seats sit above the grid for candidates with benchmark disabilities, 5 of them with a fellowship and 2 without, in the same matrix, and all 7 were still showing as vacant on the phase IV sheet. Three more entitlements sit outside the 150 entirely and belong to the system rather than to this campus: a 5% sponsored quota, a 5% quota for foreign nationals and OCI or PIO cardholders, and a floor of not less than 3% for the disability category, per the Masters information brochure.

The doctoral grid is a different animal, and it is tiny. The 2026 round gave Raebareli 4 institute-funded seats, split as 2 in Medicinal Chemistry and one each in Pharmacology & Toxicology and Pharmaceutics, and no block whatever in the project-funded half of the NIPER JEE 2026 Ph.D. seat matrix. Biotechnology, the fourth discipline that runs a doctorate here, got nothing through the entrance test at all. Every other doctoral place on this campus is filled through the direct round instead.

A different number circulates as this institute's capacity and it describes something else. Its sanctioned postgraduate intake was 100 seats for 2024-25 against 110 for 2023-24, in the NIRF 2026 data submission, and sanctioned strength is what the campus is approved to hold rather than what counselling puts in front of candidates. Counselling offered 150 in 2026-27 against a sanction of 100 the year before, which is one more reason to read the seat matrix rather than a highlights box.

The most recent Pharmacy table of the National Institutional Ranking Framework puts this institute 17th on a score of 66.65, in the 2025 ranking. That is the best any institution in Uttar Pradesh managed, by a single place: Amity University follows at 18 on 66.27.

Two things in that column need separating. The 2022 edition is an outlier that has never repeated: the score fell to 54.41 and the rank to 27 in the 2022 table, then recovered to 63.58 and 14 the following year in the 2023 table. Since that recovery the score has risen in every edition while the rank has gone the other way, from 14 in 2024 to 17 in 2025. Improving and slipping at the same time means the field around you improved faster, and it is the honest way to read this record.

The research parameter is where the recovery actually happened. Research and Professional Practice was 31.94 in the 2022 table and 52.12 in the 2025 one, a bigger gain over three editions than any other parameter on the card. Perception is the one that has stalled: it peaked at 52.62 in 2023, fell to 50.75 in 2024 and 49.63 in 2025, a slide in every edition since. Reputation is the one input an institute cannot file its way out of, and being known by a name that does not match its postal address will not have helped. The institute files in the NIRF Overall category as well, publishing its 2026 Overall submission on its own site, though its ranked appearance in 2025 was in the Pharmacy table alone.

Count the departments here and the answer depends on which institute document you open. The courses page lists eight disciplines with their own eligibility rules, Medicinal Chemistry, Pharmaceutical Analysis, Pharmaceutics, Pharmacology & Toxicology, Regulatory Toxicology, Regulatory Affairs, Biotechnology and Medical Devices, and says nothing about the M.Tech. Biopharmaceuticals seats the 2026 counselling actually offered. The research laboratories page is narrower still: only five subjects have a named instrument list behind them, Medicinal Chemistry, Pharmaceutics, Pharmacology & Toxicology, Biotechnology and Medical Devices. Two departments also share a head, since Prof. Rakesh K. Singh is described as Dean and Head of Pharmacology & Toxicology and Regulatory Toxicology on the awards page. If your discipline is one that has neither a laboratory page nor a doctoral programme, ask where it is physically housed before you accept.

Then comes the fact that should shape a two-year plan. Doctoral programmes run in four disciplines only, Medicinal Chemistry, Pharmaceutics, Pharmacology and Toxicology, and Biotechnology, per the Masters information brochure, and the institute's own direct Ph.D. advertisement invites applications in exactly those four. A masters in Regulatory Affairs, Regulatory Toxicology, Pharmaceutical Analysis or Medical Devices therefore has no doctoral continuation on this campus under its own name, which matters if the plan is to stay put after the second year.

What each department actually works on is set out at some length in the Masters information brochure. Medicinal Chemistry designs and synthesises antitubercular agents and treatments for Alzheimer's; Pharmaceutics builds nanoemulsions, drug nanofibers, nanocrystals and mesoporous silica particles aimed at the brain; Pharmaceutical Analysis works on method development and stability studies using the 500 MHz NMR, LC-MS and HRMS on site; Biotechnology works on RNA-based therapeutics, protein misfolding and polymer nanodrugs; and Medical Devices, the newest of the eight, works on in-vitro diagnostics and biomaterial-based devices.

Five acres does not buy a large campus, so what matters here is what sits inside the laboratories. The major-instrument list published for candidates runs to a 500 MHz NMR, an atomic force microscope, a scanning electron microscope, a 3D bioprinter, freeze dryers, differential scanning calorimetry, confocal microscopy, an in vivo animal imaging system, a rodent anaesthesia system, a digital stereotaxic apparatus, an animal motion tracking system and a behavioural set including T maze and elevated plus maze rigs, in the Masters information brochure. Half of that inventory only makes sense if you are running live animals, which is exactly what the departmental briefs in the same document describe.

That equipment is not reserved for students, and the institute is unusually open about the terms. Its Central Instrumentation Facility publishes a rate card for outside users, charging a government organisation ₹1500 a sample for LC-MS against ₹3000 for a private one, ₹400 and ₹600 for a proton NMR run, ₹650 and ₹800 for carbon-13, and ₹500 an hour against ₹1500 for the double-beam UV-visible spectrophotometer, with 18% GST on top, on its instruments and test facilities page. A department that sells time on its own instruments is a department that has to keep them working.

The accounts show the balance shifting from buying equipment to winning grants. Spending on new laboratory equipment fell across three years, from ₹3,89,37,689 in 2022-23 to ₹3,79,41,003 in 2023-24 and ₹1,71,47,425 in 2024-25, while sponsored research went the other way: 14 projects worth ₹74,86,798 became 20 worth ₹1,54,51,911 and then 31 projects worth ₹2,41,01,203, all in the NIRF 2026 data submission. Patents moved with the research money rather than with the equipment budget: 8 published in 2022 and 12 in 2024, with the institute's first 4 grants arriving in that last year.

Accessibility is answered identically in both of the last two filings. Lifts or ramps and specially designed toilets are reported in more than 80% of buildings in the NIRF 2026 and the NIRF 2025 submissions alike, alongside walking aids and transport between blocks. Those answers describe five acres at Sarojini Nagar, though, and a candidate who will still be enrolled when Vinayak Pur opens should ask whether they will carry across to it.

Beds here are shared, and there are fewer of them than there are students. The boys' hostel holds 140 and the girls' hostel 89, in rooms taking three and four students each, both inside the transit campus at Lucknow, on the institute's hostel page. Set that against the roll in the most recent filing, 116 men and 90 women in the two-year masters programmes plus 84 full-time doctoral scholars, in the NIRF 2026 data submission, and the arithmetic explains the wording of the promise: accommodation is offered on the availability of rooms, including shared accommodation, in the NIPER JEE 2026 Masters information brochure. A room is not attached to the seat.

What a room buys beyond the bed is basic furniture, round-the-clock internet, security guards, housekeeping, and gym and sports facilities in the block, on the hostel page. The mess is run by the students themselves rather than by a contractor. The rules on that page are stricter than most: no entry or exit between 9:30 PM and 5:00 AM without specific permission, permission required to leave campus at all, no outsiders in the hostel, and a written note to the warden before a parent visits.

The teaching bench grew and was promoted in the same year. The NIRF 2026 data submission numbers its faculty entries from 1 to 29, every one holding a doctorate and every one recorded as still working at the institute. Its NIRF 2025 submission a year earlier ran to 28, but four of those carried a leaving date, so 24 in post became 29 rather than 28 becoming 29.

Compare the two lists name by name and seven people moved up a grade in twelve months. Dr Abha Sharma and Dr Sanjay Tiwari go from associate professor to professor, Dr Nihar Ranjan from assistant professor straight to professor, and Dr Gopal Lal Khatik, Dr Keerti Jain, Dr Ashok K Datusalia and Dr Awesh Yadav from assistant to associate. All seven joined between 2010 and 2021, which is what a young bench being kept rather than replaced looks like. Prof Shubhini A Saraf has led the institute since 21-12-2022, in the NIRF 2026 data submission.

Read the association-type column before you read the headcount, though. Only 17 of the 29 entries are regular appointments; 4 are adhoc or contractual, 3 are visiting and 5 are filed as other, in the same submission. Against that stand 206 masters students and 84 full-time doctoral scholars on the roll, so the supervision arithmetic is tighter than 29 makes it look, and it is worth asking your prospective department how many of its own supervisors are permanent. Eight of the 29 entries are women. Four faculty were named in the 2025 SciRank Global Registry's top 5% of scientists, Prof. Rakesh K. Singh, Dr. Ashok Kumar Datusalia, Dr. Sandeep Chandrashekharappa and Dr. Keerti Jain, on the institute's awards page.

Graduates are almost never named on this website, and the two places you would expect to find them do not deliver. The alumni association link on the home page opens the association's constitution rather than a directory. The only former student named anywhere on the site is Dr. Lachhman Singh, a past doctoral scholar of Pharmaceutical Analysis and Medicinal Chemistry, recorded on the awards page as the 2026 winner in pharmaceutical chemistry at the PharmInnova Research Competition.

What the institute does publish is the shape of its output, and for a research degree that is the more useful thing. Its library holds 715 master's theses against 17 doctoral ones, which tells you where the volume is and how recently the doctoral school started producing. Doctoral graduates numbered 3 in 2022-23 and 5 in each of the two years after that, in the NIRF 2026 data submission. Current doctoral scholars are listed by year of admission and by department on the students page, which is the practical route to somebody who can describe a laboratory you are considering.

August 2026 was an admissions month at this campus and both of its notices are worth reading as signals. The on-spot round for the remaining Medical Devices seats ran on 18 August, and the direct doctoral round ran alongside it with applications closing on 21 August 2026, both posted on the home page. An institute filling seats in the third week of August is an institute whose intake is still open long after the national counselling has closed.

The rest of the noticeboard leans the same way the seat matrix does, towards regulatory work and towards animals. An industry-integrated experiential training programme in drug regulatory affairs is advertised for September to November 2026, and a workshop on laboratory animal science covering regulatory science and therapeutic development takes registrations until 4 September 2026, both on the home page. The Centre of Excellence in Novel Drug Delivery Systems is staffing up separately, with advertisements for a research manager and a technical assistant on its CoE page and the research manager result already declared. A quarterly newsletter, most recently the April to June 2026 issue, is the closest thing this institute has to a running record of its own year.

The comparison a school leaver would want to make, against the pharmacy colleges they could apply to at 18, does not work here, since nothing below masters level is taught. Two comparisons that do work point in opposite directions, and the first is local.

Three of those six are in Lucknow, and one of them is a collaborator: Babasaheb Bhimrao Ambedkar University signed an agreement with this institute to share faculty and research facilities in 2020, on the collaborations page. Uttar Pradesh is not short of pharmacy teaching, and most of what the state offers is undergraduate. Postgraduate research capacity is the scarce thing, and that is what this campus supplies.

The second comparison is against the six institutes that share its name, where the entrance paper, the fee schedule and the ₹12,400 stipend are one document for all seven. Seat count is the wrong place to look for the difference: Raebareli and Ahmedabad both offered 150 in the NIPER JEE 2026 seat matrix, yet every Ahmedabad seat in that grid carries a fellowship and 50 of Raebareli's do not. Only three campuses put unfunded science seats into the 2026-27 grid at all, Hajipur, Mohali and this one, in the seat availability tables of the Masters information brochure, and Mohali is the only other one that teaches Regulatory Toxicology. If the discipline you want is Regulatory Affairs, the comparison is over before it starts, because no other NIPER offers it in either column.

Everything below is a Lucknow address, including the one printed on the institute's own letterhead, and it will stay that way until the Vinayak Pur campus opens. Masters admission queries belong to the NIPER JEE office at Mohali rather than to any of these desks; everything else belongs here.

Where the institute has built its working relationships tells you where it actually lives. Its collaborations page lists agreements with CSIR-CDRI, CSIR-CIMAP, CSIR-IITR, the Centre of Biomedical Research, SGPGIMS, King George's Medical University, Lucknow University, Babasaheb Bhimrao Ambedkar University, IIIT Lucknow, Era University and the State Takmil-ut-Tib College, every one of them in Lucknow. Exactly one partner is in Raebareli, AIIMS Raebareli, signed in August 2023. A student choosing this institute for its scientific neighbourhood is choosing Lucknow's, at least for now.

At a glance

Quick facts